Home LiteratureArticle Details
PMID: 11256966 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent.

The Biochemical journal ·Vol. 355 ·No. Pt 1 ·2001-04-01 ·Pages 215-22

Vilchis-Landeros MM, Montiel JL, Mendoza V, Mendoza-Hernández G, López-Casillas F

Abstract

Betaglycan is an accessory receptor of members of the transforming growth factor-beta (TGF-beta) superfamily, which regulates their actions through ligand-dependent interactions with type II receptors. A natural soluble form of betaglycan is found in serum and extracellular matrices. Soluble betaglycan, prepared as a recombinant protein using the baculoviral expression system, inhibits the actions of TGF-beta. Because of its potential use as an anti-TGF-beta therapeutic agent, we have purified and characterized baculoviral recombinant soluble betaglycan. Baculoviral soluble betaglycan is a homodimer formed by two 110 kDa monomers associated by non-covalent interactions. This protein is devoid of glycosaminoglycan chains, although it contains the serine residues, which, in vertebrate cells, are modified by these carbohydrates. On the other hand, mannose-rich carbohydrates account for approximately 20 kDa of the mass of the monomer. End-terminal sequence analysis of the soluble betaglycan showed that Gly(24) is the first residue of the mature protein. Similarly to the natural soluble betaglycan, baculoviral soluble betaglycan has an equilibrium dissociation constant (K(d)) of 3.5 nM for TGF-beta1. Ligand competition assays indicate that the relative affinities of recombinant soluble betaglycan for the TGF-beta isoforms are TGF-beta2>TGF-beta3>TGF-beta1. The anti-TGF-beta potency of recombinant soluble betaglycan in vitro is 10-fold higher for TGF-beta2 than for TGF-beta1. Compared with a commercial pan-specific anti-TGF-beta neutralizing antibody, recombinant soluble betaglycan is more potent against TGF-beta2 and similar against TGF-beta1. These results indicate that baculoviral soluble betaglycan has the biochemical and functional properties that would make it a suitable agent for the treatment of the diseases in which excess TGF-beta plays a central physiopathological role.

MeSH Terms
Amino Acid Sequence Animals Baculoviridae/genetics Base Sequence Cell Line DNA, Complementary Dimerization Glycosylation Molecular Sequence Data Protein Isoforms/antagonists & inhibitors Proteoglycans/chemistry,genetics,pharmacology Receptors, Transforming Growth Factor beta/chemistry,genetics Recombinant Proteins/chemistry,genetics,pharmacology Transforming Growth Factor beta/antagonists & inhibitors
Chemicals
DNA, Complementary Protein Isoforms Proteoglycans Receptors, Transforming Growth Factor beta Recombinant Proteins Transforming Growth Factor beta betaglycan
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Vilchis-Landeros M M
Departmento de Biología Celular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Apartado Postal 70-246, Mexico City, D.F. 04510, México.
Montiel J L
Mendoza V
Mendoza-Hernández G
López-Casillas F
References (50)
50 references, click to expand
  1. Subtypes of betaglycan and of type I and type II transforming growth factor-beta (TGF-beta) receptors with different affinities for TGF-beta 1 and TGF-beta 2 are exhibited by human placental trophoblast cells.
    J Cell Physiol. 1992 Feb;150(2):334-43 PMID: 1310325
  2. DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS.
    Ann N Y Acad Sci. 1964 Dec 28;121:404-27 PMID: 14240539
  3. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease.
    Nature. 1992 Nov 26;360(6402):361-4 PMID: 1280332
  4. TGF beta signals through a heteromeric protein kinase receptor complex.
    Cell. 1992 Dec 11;71(6):1003-14 PMID: 1333888
  5. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta).
    Growth Factors. 1993;8(1):1-9 PMID: 8448037
  6. Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta.
    J Cell Biol. 1989 Dec;109(6 Pt 1):3137-45 PMID: 2592419
  7. The oligosaccharides of influenza virus hemagglutinin expressed in insect cells by a baculovirus vector.
    Virology. 1990 Feb;174(2):418-29 PMID: 2407026
  8. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1.
    Nature. 1990 Jul 26;346(6282):371-4 PMID: 2374609
  9. Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms.
    J Biol Chem. 1990 Nov 25;265(33):20533-8 PMID: 1700790
  10. The transforming growth factor-beta family.
    Annu Rev Cell Biol. 1990;6:597-641 PMID: 2177343
  11. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system.
    Cell. 1991 Nov 15;67(4):785-95 PMID: 1657406
  12. Expression cloning and characterization of the TGF-beta type III receptor.
    Cell. 1991 Nov 15;67(4):797-805 PMID: 1657407
  13. Purification of the transforming growth factor-beta (TGF-beta) binding proteoglycan betaglycan.
    J Biol Chem. 1991 Dec 5;266(34):23282-7 PMID: 1744125
  14. Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta.
    Lancet. 1992 Jan 25;339(8787):213-4 PMID: 1346175
  15. Betaglycan presents ligand to the TGF beta signaling receptor.
    Cell. 1993 Jul 2;73(7):1435-44 PMID: 8391934
  16. The transforming growth factor beta receptors types I, II, and III form hetero-oligomeric complexes in the presence of ligand.
    J Biol Chem. 1993 Oct 25;268(30):22215-8 PMID: 7693660
  17. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms.
    Genes Dev. 1994 Jan;8(2):133-46 PMID: 8299934
  18. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites.
    J Cell Biol. 1994 Feb;124(4):557-68 PMID: 8106553
  19. TGF-beta receptors and actions.
    Biochim Biophys Acta. 1994 May 26;1222(1):71-80 PMID: 8186268
  20. The types II and III transforming growth factor-beta receptors form homo-oligomers.
    J Cell Biol. 1994 Jul;126(1):139-54 PMID: 8027173
  21. Mapping of the ligand binding domain of the transforming growth factor beta receptor type III by deletion mutagenesis.
    Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6997-7001 PMID: 8041735
  22. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta.
    Biochem J. 1994 Sep 1;302 ( Pt 2):527-34 PMID: 8093006
  23. Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2.
    J Biol Chem. 1995 Jun 2;270(22):13567-72 PMID: 7768960
  24. Analysis of the interaction between two TGF-beta-binding proteins and three TGF-beta isoforms using surface plasmon resonance.
    Ann N Y Acad Sci. 1995 Sep 7;766:300-2 PMID: 7486677
  25. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice.
    Diabetes. 1996 Apr;45(4):522-30 PMID: 8603776
  26. Betaglycan has multiple binding sites for transforming growth factor-beta 1.
    Biochem J. 1996 May 1;315 ( Pt 3):815-20 PMID: 8645162
  27. The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice.
    Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5877-82 PMID: 8650186
  28. Endoglin modulates cellular responses to TGF-beta 1.
    J Cell Biol. 1996 Jun;133(5):1109-21 PMID: 8655583
  29. TGF-beta in kidney fibrosis: a target for gene therapy.
    Kidney Int. 1997 May;51(5):1388-96 PMID: 9150449
  30. Role of the juxtamembrane domains of the transforming growth factor-alpha precursor and the beta-amyloid precursor protein in regulated ectodomain shedding.
    J Biol Chem. 1997 Jul 4;272(27):17160-5 PMID: 9202036
  31. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung.
    J Clin Invest. 1997 Aug 15;100(4):768-76 PMID: 9259574
  32. Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells.
    J Biol Chem. 1997 Oct 3;272(40):25367-72 PMID: 9312157
  33. Hepatic fibrosis as wound repair: a progress report.
    J Gastroenterol. 1998 Apr;33(2):295-302 PMID: 9605966
  34. Murine betaglycan primary structure, expression and glycosaminoglycan attachment sites.
    Biochim Biophys Acta. 1998 May 19;1384(2):189-96 PMID: 9659379
  35. TGF-beta signal transduction.
    Annu Rev Biochem. 1998;67:753-91 PMID: 9759503
  36. Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart.
    Science. 1999 Mar 26;283(5410):2080-2 PMID: 10092230
  37. Specificity, diversity, and regulation in TGF-beta superfamily signaling.
    FASEB J. 1999 Dec;13(15):2105-24 PMID: 10593858
  38. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.
    Nature. 2000 Mar 23;404(6776):411-4 PMID: 10746731
  39. Role of transforming growth factor beta in human disease.
    N Engl J Med. 2000 May 4;342(18):1350-8 PMID: 10793168
  40. Transforming growth factor beta contributes to progressive diabetic nephropathy.
    Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7667-9 PMID: 10884396
  41. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.
    Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8015-20 PMID: 10859350
  42. TGFbeta signaling in growth control, cancer, and heritable disorders.
    Cell. 2000 Oct 13;103(2):295-309 PMID: 11057902
  43. Subunit structure of a high-affinity receptor for type beta-transforming growth factor. Evidence for a disulfide-linked glycosylated receptor complex.
    J Biol Chem. 1985 Jun 10;260(11):7059-66 PMID: 2987240
  44. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product.
    Mol Cell Biol. 1985 Dec;5(12):3610-6 PMID: 3915782
  45. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure.
    Proc Natl Acad Sci U S A. 1987 May;84(10):3365-9 PMID: 2437578
  46. Chemical deglycosylation of glycoproteins.
    Methods Enzymol. 1987;138:341-50 PMID: 2439874
  47. Membrane binding characteristics of two forms of transforming growth factor-beta.
    J Biol Chem. 1987 Oct 25;262(30):14655-62 PMID: 2889729
  48. Modifying secretion and post-translational processing in insect cells.
    Curr Opin Biotechnol. 1999 Apr;10(2):142-5 PMID: 10209136
  49. DISC ELECTROPHORESIS. I. BACKGROUND AND THEORY.
    Ann N Y Acad Sci. 1964 Dec 28;121:321-49 PMID: 14240533
  50. Transforming growth factor-beta in disease: the dark side of tissue repair.
    J Clin Invest. 1992 Jul;90(1):1-7 PMID: 1634602
Article Info
Journal
The Biochemical journal
Abbr.
Biochem J
ISSN
0264-6021
DOI
10.1042/0264-6021:3550215
Published
2001-04-01
Pages
215-22
Language
English
Region
England
NLM ID
2984726R
PMCID
PMC1221729
Subset
IM
External Links
PubMed source DOI: 10.1042/0264-6021:3550215 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2